Prosecution Insights
Last updated: November 04, 2026
Application No. 18/791,899

KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

Non-Final OA §101§102§103§DOUBLEPATENT
Filed
Aug 01, 2024
Priority
Nov 11, 2013 — provisional 61/902,635 +6 more
Examiner
HOFFMAN, SUSAN COE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kuality Herbceutics LLC
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
591 granted / 1091 resolved
-5.8% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
65 currently pending
Career history
1175
Total Applications
across all art units

Statute-Specific Performance

§101
10.5%
-29.5% vs TC avg
§103
35.5%
-4.5% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
27.6%
-12.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1091 resolved cases

Office Action

§101 §102 §103 §DOUBLEPATENT
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. The amendment filed August 21, 2026 has been received and entered. Claims 116 and 134-152 are currently pending. Election/Restrictions 3. Applicant’s election of Group I, claims 116 and 136-152, and dihydromethysticin for the species in the reply filed on August 21, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). 4. Claims 134 and 135 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. 5. Claims 116 and 136-152 are examined on the merits. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. 6. Claims 116, 136, 138, 143, 144, 149-152 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a natural product without significantly more. MPEP § 2106 sets forth the Subject Matter Eligibility Test to determine if a claim is directed to patent eligible subject matter. Step 1 asks if a claim is directed to a statutory category of invention. Applicant’s claims are directed to a product; thus, the answer to Step 1 is Yes. The analysis then moves to Step 2A, Prong One, which asks if a claim recites to a product of nature. In this case, applicant’s claims recite dihydromethysticin where the composition contains less than 0.3% by weight of flavokawain B and A and is substantially free of compounds specified in claims 149-151. Dihydromethysticin is a naturally occurring compound. Thus, the claims do recite a product of nature. MPEP § 2106.04(b) states that “When a claim recites a nature-based product limitation, examiners should use the markedly different characteristics analysis discussed in MPEP § 2106.04(c) to evaluate the nature-based product limitation and determine the answer to Step 2A.” MPEP § 2106.04(c)(I) states that “if the nature-based product limitation is not naturally occurring, for example due to some human intervention, then the markedly different characteristics analysis must be performed to determine whether the claimed product limitation is a product of nature exception…”. To perform the markedly different characteristic analysis, MPEP § 2106.04(c)(II) states “The markedly different characteristics analysis compares the nature-based product limitation to its naturally occurring counterpart in its natural state. Markedly different characteristics can be expressed as the product’s structure, function, and/or other properties…”. In this case, the claims 116 and 149-152 read on dihydromethysticin itself. Thus, the claims 116 and 149-162 are drawn directly to a product of nature. Therefore, there can be no markedly distinct characteristic between the closest occurring natural counterpart and the claimed invention because they are one and the same. Therefore, the answer to Step 2A, Prong One, is Yes. Thus, the analysis must move to Step 2A, Prong Two, which asks if the claim recites additional elements that integrate the judicial exception into a practical application. As discussed in MPEP § 2106.04(d)(2) this evaluation is performed by identifying whether there are additional elements recited in the claim beyond the judicial exception and evaluating these additional elements to determine whether the claim as a whole integrates the exception into a practical application. In this case, applicant’s claims are directed to a composition with a formulation as a “unit dosage” . MPEP § 2106.04(d)(2) specifically states that a claim is only directed to “an intended use of a claimed invention or a field of use limitation, then it cannot integrate a judicial exception under the ‘treatment or prophylaxis’ consideration.” Therefore, applicant’s intended use is not sufficient to integrate the judicial exception into a practical application because “unit dosage” form can be satisfied by the judicial exception itself. Thus, the answer to Step 2A, Prong Two, is No. Thus, the analysis must move to Step 2B which asks if claims recite additional elements that amount to significantly more than the judicial exception. MPEP § 2106.05 states that this evaluation is performed by “Evaluating additional elements to determine whether they amount to an inventive concept requires considering them both individually and in combination to ensure that they amount to significantly more than the judicial exception itself.” In this case, the additional element in the claims is the combination of the dihydromethysticin with solid carriers or a liquid to form a drink, spray, elixir, or suspension. However, MPEP § 2106.05(d) states that well-understood, routine, and conventional activities are not sufficient to show that the claims amount to significantly more than the judicial exception. Mixing specific a compound with naturally occurring carriers does not amount to significantly more than a combination of judicial exception because mixing compounds is well-understood, routine, and conventional in the field. Thus, mixing the ingredients together does not amount to significantly more than a combination of judicial exception because mixing compounds is well-understood, routine, and conventional in the field. In addition, applicant’s intended use of as a dosage form is not considered to amount to significantly more. As discussed in MPEP § 2106.05(I)(A), “Generally linking the use of the judicial exception to a particular technological environment or field of use” is not considered to be enough to qualify as significantly more. An intended use of a claimed composition only generally links the exception to the field of use. Therefore, the additional elements are not considered to amount to significantly more. Thus, the answer to Step 2B is No. Consequently, the claims are not directed to patent eligible subject matter. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 7. Claim(s) 116, 136-138, and 149-152 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Macdonough (US 2004/0047967). This reference teaches a beverage composition that contains dihydromethysticin and microcrystalline cellulose (see paragraph 16 and claims 1-3 and 7). The reference does not require flavokawain B or A or any of the compounds recited by applicant in claims 149-151. 8. Claim(s) 116, 136, 138, 143, 146 and 149-152 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Rosenbaum (US 5,585,386). This reference teaches a cream, gel, or spray composition that contains dihydromethysticin (see claims 1, 7, 25, and 26). The reference does not require flavokawain B or A or any of the compounds recited by applicant in claims 149-151. 9. Claim(s) 116, 136, 138-140, 142 and 148-152 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gow (US 2004/0071794). This reference teaches a composition containing kavalactones extracted from kava. The reference teaches that the composition contains dihydromethysticin and less than 3% flavokawain B and flavokawain A (see paragraphs 80-86). The reference teaches that the composition is formulated as a ingestible tablet, rapid-dissolve (buccal) tablet, capsule or wafer (see paragraphs 2, 4, and 27). The composition is not taught as containing any of the compounds recited by applicant in claims 149-151. 10. Claim(s) 116, 136, 138, 139, 141, 142, 143, 145 and 149-152 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chen (US 2003/0229137). This reference teaches a dosage form that contains dihydromethysticin. The reference teaches that the composition can be formulated as a tablet, capsule, lozenge (troche), spray, or patch (see paragraphs 9, 10, 12, 24, 28, and 29). The reference does not require flavokawain B or A or any of the compounds recited by applicant in claims 149-151. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. 11. Claim(s) 116, 138, 114, and 147 is/are rejected under 35 U.S.C. 103 as being unpatentable over Gow (US 2004/0071794) OR Chen (US 2003/0229137). As discussed above, each of Gow and Chen teach formulating dihydromethysticin for oral administration. Neither reference specifically teaches formulating the dihydromethysticin into a syrup or a gum. However, each of these formulations are well known in the art to be appropriate for formulating oral pharmaceutical compositions. Thus, an artisan would have been motivated to modify either Gow or Chen to include formulation of the dihydromethysticin into a gum or a syrup. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 12. Claims 116 and 136-152 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 10,624,943. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a composition comprising dihydromethysticin where the composition is substantially free of flavokawain B or A and any of the compounds recited by applicant in claims 149-151. The composition is formulated as a tablet, capsule, wafer, gum, nano-emulsion, cream, or gel. The claims of US ‘943 do not teach the use of microcrystalline cellulose or the other formulations claimed by applicant. However, microcrystalline cellulose and the other formulations claimed by applicant are well known in the art to be appropriate to use for oral pharmaceuticals. Thus, an artisan of ordinary skill would be motivated to modify the claims of US ‘943 to include microcrystalline cellulose and the other formulations claimed by applicant. 13. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Aug 01, 2024
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779000
Processes for Extracting Muscimol from Amanita Muscaria
3y 1m to grant Granted Nov 03, 2026
Patent 12766178
SKIN CLARIFIER
5y 0m to grant Granted Oct 20, 2026
Patent 12766176
DEBITTERING KUDINGCHA EXTRACT, PREPARATION METHOD AND FINGERPRINT DETECTION METHOD THEREOF
3y 8m to grant Granted Oct 20, 2026
Patent 12766180
Fagopyrum Nutraceutical Compositions
2y 7m to grant Granted Oct 20, 2026
Patent 12758602
ANTI-INFLAMMATORY COMPOSITION COMPRISING EPIMENDIUM KOREANUM NAKAI, POLYGALA TENUIFOLIA WILD, AND POLYPORUS UMBELLATUS FRIES EXTRACTS OR MIXTURE THEREOF AS ACTIVE INGREDIENT
3y 1m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
80%
With Interview (+25.7%)
2y 11m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1091 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month